https://scholars.lib.ntu.edu.tw/handle/123456789/636972
標題: | Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study | 作者: | Dai, Ming-Shen Chao, Ta-Chung Chiu, Chang-Fang YEN-SHEN LU Shiah, Her-Shyong Jackson, Christopher G C A Hung, Noelyn Zhi, Jianguo Cutler, David L Kwan, Rudolf Kramer, Douglas Chan, Wing-Kai Qin, Albert Tseng, Kuan-Chiao Hung, Cheung Tak Chao, Tsu-Yi |
關鍵字: | HM30181A; P-gp inhibitor; efficacy; encequidar; oral paclitaxel; pharmacokinetics; safety | 公開日期: | 2023 | 卷: | 15 | 來源出版物: | Therapeutic advances in medical oncology | 摘要: | Paclitaxel is widely used for the treatment of metastatic breast cancer (MBC). However, it has a low oral bioavailability due to gut extrusion caused by P-glycoprotein (P-gp). Oral paclitaxel (oPAC) may be more convenient, less resource-intensive, and more tolerable than its intravenous form. Encequidar (E) is a first-in-class, minimally absorbed, gut-specific oral P-gp inhibitor that facilitates the oral absorption of paclitaxel. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/636972 | ISSN: | 1758-8340 | DOI: | 10.1177/17588359231183680 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。